36 results on '"Barnhart, Kurt T."'
Search Results
2. Contraceptive efficacy, safety, fit, and acceptability of a single-size diaphragm developed with end-user input.
- Author
-
Schwartz JL, Weiner DH, Lai JJ, Frezieres RG, Creinin MD, Archer DF, Bradley L, Barnhart KT, Poindexter A, Kilbourne-Brook M, Callahan MM, and Mauck CK
- Subjects
- Acrylic Resins adverse effects, Adult, Equipment Design, Female, Humans, Male, Nonoxynol adverse effects, Patient Satisfaction, Propensity Score, Young Adult, Contraceptive Devices, Female adverse effects, Pregnancy statistics & numerical data, Spermatocidal Agents adverse effects, Vaginal Creams, Foams, and Jellies adverse effects
- Abstract
Objective: To estimate contraceptive efficacy, safety, acceptability, and fit of a single-size diaphragm used with contraceptive gel., Methods: We conducted a multicenter trial in which 450 couples used the single-size diaphragm, 300 randomized to acid-buffering gel and 150 to nonoxynol-9, for at least 190 days and six menstrual cycles. Visits were at enrollment and after menstrual cycles 1, 3, and 6. Study outcomes included pregnancy probability, safety, acceptability, and fit. Pregnancy and safety were compared with an historical control group who used a standard diaphragm with these gels., Results: Most (439/450 [98%]) women could be fitted with the single-size diaphragm. A total of 421 of 450 (94%) provided follow-up. The 35 study pregnancies yielded 6-month Kaplan-Meier cumulative typical use pregnancy probabilities per 100 women with 95% confidence intervals (CIs) of 10.4 (6.9-14.0) for all users and 9.6 (5.5-13.6) and 12.5 (5.4-19.5) with acid-buffering gel and nonoxynol-9, respectively. Historical control analysis yielded a propensity score-adjusted estimate of this pregnancy probability for the single-size diaphragm of 11.3 compared with 10.7 per 100 women for the standard diaphragm ([rounded] difference 0.7, 95% CI -3.6 to 4.9). Approximately half (51%) reported at least one urogenital event but compared favorably to the standard diaphragm in historical control analysis. Most (282/342 [82%]) liked the diaphragm. Results suggest that if provided by a clinician, 94% (95% CI 92-96%) could insert, correctly position, and remove the diaphragm., Conclusion: The single-size diaphragm was safe, as effective as a standard diaphragm, and acceptable when used with contraceptive gel., Clinical Trial Registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00578877.
- Published
- 2015
- Full Text
- View/download PDF
3. The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial.
- Author
-
Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Alvero R, Casson P, Christman GM, Huang H, Yan Q, Haisenleder DJ, Barnhart KT, Bates GW, Usadi R, Lucidi R, Baker V, Trussell JC, Krawetz SA, Snyder P, Ohl D, Santoro N, Eisenberg E, and Zhang H
- Subjects
- Adult, Double-Blind Method, Female, Fertility Agents, Female pharmacology, Fertility Agents, Female therapeutic use, Humans, Male, Obesity drug therapy, Polycystic Ovary Syndrome drug therapy, Young Adult, Obesity diagnosis, Obesity epidemiology, Polycystic Ovary Syndrome diagnosis, Polycystic Ovary Syndrome epidemiology, Pregnancy drug effects
- Abstract
Objective: To summarize baseline characteristics from a large multicenter infertility clinical trial., Design: Cross-sectional baseline data from a double-blind randomized trial of two treatment regimens (letrozole vs. clomiphene)., Setting: Academic Health Centers throughout the United States., Patient(s): Seven hundred fifty women with polycystic ovary syndrome (PCOS) and their male partners took part in the study., Intervention(s): None., Main Outcome Measure(s): Historic, biometric, biochemical, and questionnaire parameters., Result(s): Females averaged 30 years and were obese (body mass index [BMI] 35) with ∼20% from a racial/ethnic minority. Most (87%) were hirsute and nulligravid (63%). Most of the women had an elevated antral follicle count and enlarged ovarian volume on ultrasound. Women had elevated mean circulating androgens, LH-to-FSH ratio (∼2), and antimüllerian hormone levels (8.0 ng/mL). In addition, women had evidence for metabolic dysfunction with elevated mean fasting insulin and dyslipidemia. Increasing obesity was associated with decreased LH-to-FSH levels, antimüllerian hormone levels, and antral follicle counts but increasing cardiovascular risk factors, including prevalence of the metabolic syndrome. Men were obese (BMI 30) and had normal mean semen parameters., Conclusion(s): The treatment groups were well matched at baseline. Obesity exacerbates select female reproductive and most metabolic parameters. We have also established a database and sample repository that will eventually be accessible to investigators., Clinical Trial Registration Number: NCT00719186., (Copyright © 2014 American Society for Reproductive Medicine. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
4. Systematic discovery of ectopic pregnancy serum biomarkers using 3-D protein profiling coupled with label-free quantitation.
- Author
-
Beer LA, Tang HY, Sriswasdi S, Barnhart KT, and Speicher DW
- Subjects
- ADAM Proteins blood, ADAM Proteins genetics, ADAM12 Protein, Amino Acid Sequence, Chromatography, Liquid methods, Databases, Protein, Electrophoresis, Polyacrylamide Gel methods, Female, Humans, Membrane Proteins blood, Membrane Proteins genetics, Molecular Sequence Data, Tandem Mass Spectrometry methods, Biomarkers blood, Blood Proteins analysis, Pregnancy blood, Pregnancy, Ectopic blood, Proteome analysis, Proteomics methods
- Abstract
Ectopic pregnancy (EP) and normal intrauterine pregnancy (IUP) serum proteomes were quantitatively compared to systematically identify candidate biomarkers. A 3-D biomarker discovery strategy consisting of abundant protein immunodepletion, SDS gels, LC-MS/MS, and label-free quantitation of MS signal intensities identified 70 candidate biomarkers with differences between groups greater than 2.5-fold. Further statistical analyses of peptide quantities were used to select the most promising 12 biomarkers for further study, which included known EP biomarkers, novel EP biomarkers (ADAM12 and ISM2), and five specific isoforms of the pregnancy specific beta-1-glycoprotein family. Technical replicates showed good reproducibility and protein intensities from the label-free discovery analysis compared favorably with reported abundance levels of several known reference serum proteins over at least 3 orders of magnitude. Similarly, relative abundances of candidate biomarkers from the label-free discovery analysis were consistent with relative abundances from pilot validation assays performed for five of the 12 most promising biomarkers using label-free multiple reaction monitoring of both the patient serum pools used for discovery and the individual samples that constituted these pools. These results demonstrate robust, reproducible, in-depth 3-D serum proteome discovery, and subsequent pilot-scale validation studies can be achieved readily using label-free quantitation strategies.
- Published
- 2011
- Full Text
- View/download PDF
5. Symptomatic patients with an early viable intrauterine pregnancy: HCG curves redefined.
- Author
-
Barnhart KT, Sammel MD, Rinaudo PF, Zhou L, Hummel AC, and Guo W
- Subjects
- Abortion, Spontaneous diagnosis, Adolescent, Adult, Female, Humans, Models, Statistical, Pregnancy, Ectopic diagnosis, Chorionic Gonadotropin blood, Pregnancy blood
- Abstract
Objective: To analyze the change in serial human chorionic gonadotropin (hCG) levels in women symptomatic with pain or bleeding who presented with nondiagnostic ultrasonography but were ultimately confirmed to have a viable intrauterine pregnancy., Methods: The rise in serial hCG measures were modeled over time, with the start point defined in 2 ways: by last menstrual period and by date of presentation for care. Both semiparametric (spline) curves and linear random-effects models were explored. The slope and projected increase of hCG were calculated to define 99% of viable intrauterine pregnancies., Results: A total of 287 subjects met inclusion criteria and contributed 861 measurements of hCG. On average, these subjects contributed 3.00 observations and were followed up for 5.25 days. A linear increase in log hCG best described the pattern of rise. Curves derived from last menstrual period and day of presentation do not differ substantially. The median slope for a rise of hCG after 1 day was 1.50, (or a 50% increase); 2.24 after 2 days (or a 124% rise), and 5.00 after 4 days. The fastest rise was 1.81 at 1 day, 3.28 at 2 days, and 10.76 at 4 days. The slowest or minimal rise for a normal viable intrauterine pregnancy was 24% at 1 day and 53% at 2 days., Conclusion: These data define the slowest rise in serial hCG values for a potentially viable gestation and will aid in distinguishing a viable early pregnancy from a miscarriage or ectopic pregnancy. The minimal rise in serial hCG values for women with a viable intrauterine pregnancy is "slower" than previously reported, suggesting that intervention to diagnosis and treat an abnormal gestation should be more conservative.
- Published
- 2004
- Full Text
- View/download PDF
6. Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device
- Author
-
Creinin, Mitchell D, Barnhart, Kurt T, Gawron, Lori M, Eisenberg, David, Mabey, R Garn, and Jensen, Jeffrey T
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Clinical Trials and Supportive Activities ,Clinical Research ,Obesity ,Good Health and Well Being ,Female ,Humans ,Pregnancy ,Intrauterine Devices ,Medicated ,Levonorgestrel ,Menorrhagia ,Prospective Studies ,Treatment Outcome ,Paediatrics and Reproductive Medicine ,Obstetrics & Reproductive Medicine ,Reproductive medicine - Abstract
ObjectiveTo evaluate heavy menstrual bleeding treatment outcomes with levonorgestrel 52-mg intrauterine device (IUD) use in participants without body mass index (BMI) or parity restrictions.MethodsInvestigators included participants aged 18-50 years with no pelvic or systemic pathology causing heavy menstrual bleeding at 29 U.S. centers in a prospective trial. Participants had up to three screening cycles with menstrual product collection for alkaline hematin blood-loss measurements. Investigators enrolled those with two menses with blood loss of 80 mL or more (values averaged for baseline blood loss), placed the IUD, and followed participants for up to six 28-day cycles. Participants collected any menstrual products used during cycles 3 and 6 for blood-loss measurement. We evaluated outcomes in participants with at least one follow-up assessment for the primary outcome of median absolute blood-loss change and, secondarily, treatment success , defined as the proportion with a final measured blood loss less than 80 mL and at least 50% reduction from baseline. We evaluated exploratory outcomes of differences in blood-loss changes by BMI and parity using Wilcoxon rank sum test.ResultsOf 105 enrolled participants, 47 (44.8%) had obesity (BMI 30.0 or higher) and 29 (27.6%) were nulliparous. Baseline mean blood loss ranged from 73 to 520 mL (median 143 mL, interquartile range 112-196 mL). Eighty-nine (84.8%) had at least one evaluable follow-up evaluation. Participants had median (interquartile range) absolute blood-loss decreases at cycles 3 (n=86) and 6 (n=81) of 93.3% (86.1-97.7%) and 97.6% (90.4-100%), respectively. At cycle 6, participants without obesity (n=43) and with obesity (n=38) had similar median [interquartile range] decreases (97.6% [91.8-100%] and 97.5% [90.3-100%], respectively; P =.89), with comparable findings for nulliparous (n=25) and parous (n=56) participants (97.0% [91.7-99.1%] and 98.1% [89.9-100%], respectively; P =.43). Treatment success occurred in 81.8% (95% CI 74.2-89.4%) of 99 participants, excluding those with no outcomes due to lost to follow-up or consent withdrawal, and did not vary by BMI or parity. The most common adverse events leading to discontinuation were bleeding or cramping (n=6 [5.7%]) and expulsion (n=5 [4.8%]).ConclusionThis levonorgestrel 52-mg IUD reduces blood loss by more than 90% over 6 months compared with baseline for most users with heavy menstrual bleeding.Funding sourceMedicines360.Clinical trial registrationClinicalTrials.gov , NCT03642210.
- Published
- 2023
7. Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss
- Author
-
Schreiber, Courtney A, Creinin, Mitchell D, Atrio, Jessica, Sonalkar, Sarita, Ratcliffe, Sarah J, and Barnhart, Kurt T
- Subjects
Clinical Research ,Prevention ,Clinical Trials and Supportive Activities ,Reproductive health and childbirth ,Good Health and Well Being ,Abortifacient Agents ,Nonsteroidal ,Abortifacient Agents ,Steroidal ,Abortion ,Spontaneous ,Administration ,Intravaginal ,Administration ,Oral ,Adult ,Drug Therapy ,Combination ,Embryo ,Mammalian ,Female ,Fetal Death ,Gestational Sac ,Hemorrhage ,Humans ,Mifepristone ,Misoprostol ,Pregnancy ,Pregnancy Trimester ,First ,Ultrasonography ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundMedical management of early pregnancy loss is an alternative to uterine aspiration, but standard medical treatment with misoprostol commonly results in treatment failure. We compared the efficacy and safety of pretreatment with mifepristone followed by treatment with misoprostol with the efficacy and safety of misoprostol use alone for the management of early pregnancy loss.MethodsWe randomly assigned 300 women who had an anembryonic gestation or in whom embryonic or fetal death was confirmed to receive pretreatment with 200 mg of mifepristone, administered orally, followed by 800 μg of misoprostol, administered vaginally (mifepristone-pretreatment group), or 800 μg of misoprostol alone, administered vaginally (misoprostol-alone group). Participants returned 1 to 4 days after misoprostol use for evaluation, including ultrasound examination, by an investigator who was unaware of the treatment-group assignments. Women in whom the gestational sac was not expelled were offered expectant management, a second dose of misoprostol, or uterine aspiration. We followed all participants for 30 days after randomization. Our primary outcome was gestational sac expulsion with one dose of misoprostol by the first follow-up visit and no additional intervention within 30 days after treatment.ResultsComplete expulsion after one dose of misoprostol occurred in 124 of 148 women (83.8%; 95% confidence interval [CI], 76.8 to 89.3) in the mifepristone-pretreatment group and in 100 of 149 women (67.1%; 95% CI, 59.0 to 74.6) in the misoprostol-alone group (relative risk, 1.25; 95% CI, 1.09 to 1.43). Uterine aspiration was performed less frequently in the mifepristone-pretreatment group than in the misoprostol-alone group (8.8% vs. 23.5%; relative risk, 0.37; 95% CI, 0.21 to 0.68). Bleeding that resulted in blood transfusion occurred in 2.0% of the women in the mifepristone-pretreatment group and in 0.7% of the women in the misoprostol-alone group (P=0.31); pelvic infection was diagnosed in 1.3% of the women in each group.ConclusionsPretreatment with mifepristone followed by treatment with misoprostol resulted in a higher likelihood of successful management of first-trimester pregnancy loss than treatment with misoprostol alone. (Funded by the National Institute of Child Health and Human Development; PreFaiR ClinicalTrials.gov number, NCT02012491 .).
- Published
- 2018
8. Diagnostic Criteria for Nonviable Pregnancy Early in the First Trimester
- Author
-
Doubilet, Peter M, Benson, Carol B, Bourne, Tom, Blaivas, Michael, Barnhart, Kurt T, Benacerraf, Beryl R, Brown, Douglas L, Filly, Roy A, Fox, J Christian, Goldstein, Steven R, Kendall, John L, Lyons, Edward A, Porter, Misty Blanchette, Pretorius, Dolores H, and Timor-Tritsch, Ilan E
- Subjects
Crown-Rump Length ,False Positive Reactions ,Female ,Fetal Death ,Fetal Viability ,Gestational Sac ,Humans ,Pregnancy ,Pregnancy Trimester ,First ,Ultrasonography ,Prenatal ,Society of Radiologists in Ultrasound Multispecialty Panel on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy ,Medical and Health Sciences ,General & Internal Medicine - Published
- 2013
9. Measuring serum estradiol and progesterone one day prior to frozen embryo transfer improves live birth rates
- Author
-
Alur-Gupta, Snigdha, Hopeman, Margaret, Berger, Dara S., Barnhart, Kurt T., Senapati, Suneeta, and Gracia, Clarisa
- Published
- 2020
- Full Text
- View/download PDF
10. Participant characteristics associated with withdrawal from a large randomized trial of spermicide effectiveness
- Author
-
Raymond, Elizabeth G, Chen, Pai Lien, Pierre-Louis, Bosny, Luoto, Joanne, Barnhart, Kurt T, Bradley, Lynn, Creinin, Mitchell D, Poindexter, Alfred, Wan, Livia, Martens, Mark, Schenken, Robert, Nicholas, Cate F, and Blackwell, Richard
- Subjects
Prevention ,Clinical Trials and Supportive Activities ,Clinical Research ,Reproductive health and childbirth ,Good Health and Well Being ,Adult ,Coitus ,Contraception Behavior ,Female ,Humans ,Longitudinal Studies ,Motivation ,Nonoxynol ,Pregnancy ,Pregnancy Tests ,Refusal to Participate ,Reproducibility of Results ,Research Design ,Research Subjects ,Risk ,Spermatocidal Agents ,Student Health Services ,United States ,Public Health and Health Services ,General & Internal Medicine - Abstract
BackgroundIn most recent large efficacy trials of barrier contraceptive methods, a high proportion of participants withdrew before the intended end of follow-up. The objective of this analysis was to explore characteristics of participants who failed to complete seven months of planned participation in a trial of spermicide efficacy.MethodsTrial participants were expected to use the assigned spermicide for contraception for 7 months or until pregnancy occurred. In bivariable and multivariable analyses, we assessed the associations between failure to complete the trial and 17 pre-specified baseline characteristics. In addition, among women who participated for at least 6 weeks, we evaluated the relationships between failure to complete, various features of their first 6 weeks of experience with the spermicide, and characteristics of the study centers and population.ResultsOf the 1514 participants in this analysis, 635 (42%) failed to complete the study for reasons other than pregnancy. Women were significantly less likely to complete if they were younger or unmarried, had intercourse at least 8 times per month, or were enrolled at a university center or at a center that enrolled fewer than 4 participants per month. Noncompliance with study procedures in the first 6 weeks was also associated with subsequent early withdrawal, but dissatisfaction with the spermicide was not. However, many participants without these risk factors withdrew early.ConclusionsFailure to complete is a major problem in barrier method trials that seriously compromises the interpretation of results. Targeting retention efforts at women at high risk for early withdrawal is not likely to address the problem sufficiently.
- Published
- 2004
11. Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial.
- Author
-
Barnhart, Kurt T., Hansen, Karl R., Stephenson, Mary D., Usadi, Rebecca, Steiner, Anne Z., Cedars, Marcelle I., Jungheim, Emily S., Hoeger, Kathleen M., Krawetz, Stephen A., Mills, Benjie, Alston, Meredith, Coutifaris, Christos, Senapati, Suneeta, Sonalkar, Sarita, Diamond, Michael P., Wild, Robert A., Rosen, Mitchell, Sammel, Mary D., Santoro, Nanette, and Eisenberg, Esther
- Subjects
- *
PREGNANCY complications , *ECTOPIC pregnancy , *METHOTREXATE , *CLINICAL trials , *PREGNANCY , *EVALUATION of medical care , *UTERINE hemorrhage , *RESEARCH , *DILATATION & curettage , *MISCARRIAGE , *RESEARCH methodology , *PATIENT satisfaction , *MEDICAL cooperation , *EVALUATION research , *ABORTIFACIENTS , *COMPARATIVE studies , *RANDOMIZED controlled trials , *RESEARCH funding , *COMBINED modality therapy , *FETAL ultrasonic imaging , *CHORIONIC gonadotropins - Abstract
Importance: Women with an early nonviable pregnancy of unknown location are at high risk of ectopic pregnancy and its inherent morbidity and mortality. Successful and timely resolution of the gestation, while minimizing unscheduled interventions, are important priorities.Objective: To determine if active management is more effective in achieving pregnancy resolution than expectant management and whether the use of empirical methotrexate is noninferior to uterine evacuation followed by methotrexate if needed.Design, Setting, and Participants: This multicenter randomized clinical trial recruited 255 hemodynamically stable women with a diagnosed persisting pregnancy of unknown location between July 25, 2014, and June 4, 2019, in 12 medical centers in the United States (final follow up, August 19, 2019).Interventions: Eligible patients were randomized in a 1:1:1 ratio to expectant management (n = 86), active management with uterine evacuation followed by methotrexate if needed (n = 87), or active management with empirical methotrexate using a 2-dose protocol (n = 82).Main Outcomes and Measures: The primary outcome was successful resolution of the pregnancy without change from initial strategy. The primary hypothesis tested for superiority of the active groups combined vs expectant management, and a secondary hypothesis tested for noninferiority of empirical methotrexate compared with uterine evacuation with methotrexate as needed using a noninferiority margin of -12%.Results: Among 255 patients who were randomized (median age, 31 years; interquartile range, 27-36 years), 253 (99.2%) completed the trial. Ninety-nine patients (39%) declined their randomized allocation (26.7% declined expectant management, 48.3% declined uterine evacuation, and 41.5% declined empirical methotrexate) and crossed over to a different group. Compared with patients randomized to receive expectant management (n = 86), women randomized to receive active management (n = 169) were significantly more likely to experience successful pregnancy resolution without change in their initial management strategy (51.5% vs 36.0%; difference, 15.4% [95% CI, 2.8% to 28.1%]; rate ratio, 1.43 [95% CI, 1.04 to 1.96]). Among active management strategies, empirical methotrexate was noninferior to uterine evacuation followed by methotrexate if needed with regard to successful pregnancy resolution without change in management strategy (54.9% vs 48.3%; difference, 6.6% [1-sided 97.5% CI, -8.4% to ∞]). The most common adverse event was vaginal bleeding for all of the 3 management groups (44.2%-52.9%).Conclusions and Relevance: Among patients with a persisting pregnancy of unknown location, patients randomized to receive active management, compared with those randomized to receive expectant management, more frequently achieved successful pregnancy resolution without change from the initial management strategy. The substantial crossover between groups should be considered when interpreting the results.Trial Registration: ClinicalTrials.gov Identifier: NCT02152696. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
12. Impact of Endometriosis on IVF Outcomes: An Evaluation of the Society for Assisted Reproductive Technologies Database
- Author
-
Senapati, Suneeta, Sammel, Mary D., Morse, Christopher, and Barnhart, Kurt T.
- Subjects
Adult ,Cryopreservation ,Time Factors ,Databases, Factual ,Pregnancy Rate ,Endometriosis ,Fertilization in Vitro ,Embryo Transfer ,Article ,Fertility ,Treatment Outcome ,Pregnancy ,Risk Factors ,Humans ,Female ,Infertility, Female ,Live Birth ,Retrospective Studies - Abstract
To assess the impact of endometriosis, alone or in combination with other infertility diagnoses, on IVF outcomes.Population-based retrospective cohort study of cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database.Not applicable.A total of 347,185 autologous fresh and frozen assisted reproductive technology cycles from the period 2008-2010.None.Oocyte yield, implantation rate, live birth rate.Although cycles of patients with endometriosis constituted 11% of the study sample, the majority (64%) reported a concomitant diagnosis, with male factor (42%), tubal factor (29%), and diminished ovarian reserve (22%) being the most common. Endometriosis, when isolated or with concomitant diagnoses, was associated with lower oocyte yield compared with those with unexplained infertility, tubal factor, and all other infertility diagnoses combined. Women with isolated endometriosis had similar or higher live birth rates compared with those in other diagnostic groups. However, women with endometriosis with concomitant diagnoses had lower implantation rates and live birth rates compared with unexplained infertility, tubal factor, and all other diagnostic groups.Endometriosis is associated with lower oocyte yield, lower implantation rates, and lower pregnancy rates after IVF. However, the association of endometriosis and IVF outcomes is confounded by other infertility diagnoses. Endometriosis, when associated with other alterations in the reproductive tract, has the lowest chance of live birth. In contrast, for the minority of women who have endometriosis in isolation, the live birth rate is similar or slightly higher compared with other infertility diagnoses.
- Published
- 2016
13. A Strict Infertility Diagnosis Has Poor Agreement with the Clinical Diagnosis Entered Into SART
- Author
-
Molinaro, Thomas A., Shaunik, Alka, Lin, Kathleen, Sammel, Mary D., and Barnhart, Kurt T.
- Subjects
Adult ,Male ,Uterine Diseases ,Pregnancy Rate ,Reproductive Techniques, Assisted ,Sperm Count ,Endometriosis ,Fallopian Tube Diseases ,Prognosis ,Article ,Pregnancy ,Sperm Motility ,Humans ,Female ,Registries ,Infertility, Female ,Diagnosis-Related Groups ,Polycystic Ovary Syndrome - Abstract
Based on a recent review of the medical literature, a clinical diagnosis of infertility may not agree with strict criteria. Standardized definitions of diagnostic categories are essential for accurate patient prognosis and future research.
- Published
- 2009
14. COST-EFFECTIVENESS ANALYSIS OF THE ACTIVE TREATMENT OR NO TREATMENT (ACT OR NOT) RANDOMIZED CONTROLLED TRIAL OF THE OPTIMAL MANAGEMENT OF PERSISTENT PREGNANCIES OF UNKNOWN LOCATION.
- Author
-
Walter, Jessica R., Barnhart, Kurt T., Koelper, Nathanael C., Santoro, Nanette F., Zhang, Heping, Thomas, Tracey R., Huang, Hao, and Harvie, Heidi
- Subjects
- *
COST effectiveness , *PREGNANCY , *THERAPEUTICS , *ECTOPIC pregnancy - Published
- 2021
- Full Text
- View/download PDF
15. Evaluation of a New Model for Human Chorionic Gonadotropin Rise in Pregnancies of Unknown Viability.
- Author
-
Bollig, Kassie J., Finlinson, Alex, Barnhart, Kurt T., Coutifaris, Christos, and Schust, Danny J.
- Subjects
- *
CHORIONIC gonadotropins , *MISCARRIAGE , *ECTOPIC pregnancy , *PREGNANCY - Abstract
The proposed human chorionic gonadotropin threshold model optimizes the balance between identifying viable intrauterine pregnancies and minimizing rates of misdiagnosis of nonviable pregnancies. OBJECTIVE: To evaluate the performance of a new human chorionic gonadotropin (hCG) threshold model to classify pregnancies as viable or nonviable using a longitudinal cohort of individuals with pregnancy of unknown viability. The secondary objective was to compare the new model with three established models. METHODS: This is a single-center, retrospective cohort study of individuals seen at the University of Missouri from January 1, 2015, until March 1, 2020, who had at least two consecutive quantitative hCG serum levels with an initial level greater than 2 milli-international units/mL and 5,000 milli-international units/mL or less, with the first interval between laboratory draws no greater than 7 days. Prevalence of correct classification of viable intrauterine pregnancies, ectopic pregnancies, and early pregnancy losses was evaluated with a new proposed hCG threshold model and compared with three established models describing minimum expected rates of hCG rise for a viable intrauterine pregnancy. RESULTS: Of an initial cohort of 1,295 individuals, 688 patients met inclusion criteria. One hundred sixty-seven individuals (24.3%) had a viable intrauterine pregnancy; 463 (67.3%) had an early pregnancy loss; and 58 (8.4%) had an ectopic pregnancy. A new model based on the total additive percent rise of hCG at 4 and 6 days after initial hCG (70% or greater and 200% or greater rise, respectively) was created. The new model was able to correctly identify 100% of viable intrauterine pregnancies while minimizing incorrect classification of early pregnancy losses and ectopic pregnancies as normal pregnancies. At 4 days after initial hCG, 14 ectopic pregnancies (24.1%) and 44 early pregnancy losses (9.5%) were incorrectly classified as potentially normal pregnancies. At 6 days after initial hCG, only seven ectopic pregnancies (12.1%) and 25 early pregnancy losses (5.6%) were incorrectly classified as potentially normal pregnancies. In established models, up to nine intrauterine pregnancies (5.4%) were misclassified as abnormal pregnancies and up to 26 ectopic pregnancies (44.8%) and 58 early pregnancy losses (12.5%) were incorrectly classified as potentially normal pregnancies. CONCLUSION: The proposed new hCG threshold model optimizes a balance between identifying potentially viable intrauterine pregnancies and minimizing misdiagnosis of ectopic pregnancies and early pregnancy losses. External validation in other cohorts is needed before widespread clinical use. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement†‡.
- Author
-
Legro, Richard S., Wu, Xiaoke, Barnhart, Kurt T., Farquhar, Cynthia, Fauser, Bart C.J.M., and Mol, Ben
- Subjects
INFERTILITY treatment ,CLINICAL trials ,LACTATION consultants ,PUBLIC health ,PREGNANCY ,FETAL abnormalities - Abstract
Clinical trials testing infertility treatments often do not report on the major outcomes of interest to patients and clinicians and the public (such as live birth) nor on the harms, including maternal risks during pregnancy and fetal anomalies. This is complicated by the multiple participants in infertility trials which may include a woman (mother), a man (father), and result in a third individual if successful, their offspring (child), who is also the desired outcome of treatment. The primary outcome of interest and many adverse events occur after cessation of infertility treatment and during pregnancy and the puerperium, which create a unique burden of follow-up for clinical trial investigators and participants. In 2013, because of the inconsistencies in trial reporting and the unique aspects of infertility trials not adequately addressed by existing Consolidated Standards of Reporting Trials (CONSORT) statements, we convened a consensus conference in Harbin, China, with the aim of planning modifications to the CONSORT checklist to improve the quality of reporting of clinical trials testing infertility treatment. The consensus group recommended that the preferred primary outcome of all infertility trials is live birth (defined as any delivery of a live infant ≥20 weeks gestations) or cumulative live birth, defined as the live birth per women over a defined time period (or number of treatment cycles). In addition, harms to all participants should be systematically collected and reported, including during the intervention, any resulting pregnancy, and during the neonatal period. Routine information should be collected and reported on both male and female participants in the trial. We propose to track the change in quality that these guidelines may produce in published trials testing infertility treatments. Our ultimate goal is to increase the transparency of benefits and risks of infertility treatments to provide better medical care to affected individuals and couples. [ABSTRACT FROM AUTHOR]
- Published
- 2014
17. Live birth is the correct outcome for clinical trials evaluating therapy for the infertile couple.
- Author
-
Barnhart, Kurt T.
- Subjects
- *
CHILDBIRTH , *INFERTILITY treatment , *REPRODUCTIVE health , *MULTIPLE birth , *PREGNANCY , *BIOMARKERS , *CLINICAL trials , *HEALTH outcome assessment - Abstract
Well-designed and -conducted clinical trials are needed to further advance the field for reproductive medicine. However, current reporting of outcomes of trials is ambiguous and disparate. In this review it is offered that the preferred outcome for clinical trials in reproductive medicine should be live birth. Multiple births should be listed, and it should be specified whether this is multiple births per couple or multiple births per conception. The unit of measure should be women (or couples) and not cycles. The duration of exposure should also be clearly identified (i.e., treatment was one cycle, a prespecified number of cycles, or a period of time). Pregnancy loss should be specified, and the denominator should be those who conceived. Although live birth is the primary outcome, complications should be defined and reported, including multiple births and other objective markers, such as preterm delivery, small-for-gestational age, or stillbirth. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
18. Hormone pattern after misoprostol administration for a nonviable first-trimester gestation
- Author
-
Barnhart, Kurt T., Bader, Thomas, Huang, Xiangke, Frederick, Margaret M., Timbers, Kelly A., and Zhang, Jun Jim
- Subjects
- *
PREGNANCY , *MISCARRIAGE , *SEX hormones , *HORMONE therapy , *LOGISTIC regression analysis - Abstract
: ObjectiveTo evaluate serial hormone concentrations in subjects treated with vaginally administered misoprostol for early pregnancy failure.: DesignAs part of a randomized clinical trial, serum was collected on treatment days 1, 3, 8, and 15.: SettingMulticenter clinical trial.: Patient(s)Women with a nonviable first-trimester pregnancy.: Intervention(s)Serum concentrations of human chorionic gonadotropin (hCG), progesterone, and sex hormone binding globulin (SHBG) were evaluated.: Main outcome measure(s)A logistic regression model was constructed to assess the associations of percent and complete expulsion of the gestational sac and/or successful management.: Result(s)The percent change from the day of treatment until the first follow-up visit was predictive for complete expulsion for progesterone (P) (P<.005) and hCG (P<.005), but not for SHBG. The actual value was not significantly associated with complete expulsion or successful management. A decrease (day 1–3) of 79% for both hCG and P was associated with a 90% probability of complete passage of the gestational sac. A 90% probability of successful management was noted if P decreased by 78% on day 3 or 59% on day 7, or hCG decreased by 74% on day 3 or 78% on day 7 compared with pretreatment values.: Conclusion(s)Percent change, but not absolute change, in serial hormone values are strongly associated with both the complete expulsion of the gestational sac with one dose of misoprostol and ultimate success. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
19. Evaluation of the Association Between Hereditary Thrombophilias and Recurrent Pregnancy Loss: A Meta-analysis.
- Author
-
Kovalevsky, George, Gracia, Clarisa R., Berlin, Jesse A., Sammel, Mary D., and Barnhart, Kurt T.
- Subjects
GENETIC disorders ,ABORTION ,GENETIC mutation ,PROTHROMBIN ,SECOND trimester of pregnancy ,META-analysis - Abstract
Background: Recurrent pregnancy loss (RPL) is a significant clinical problem. Recently, thrombophilias have been implicated as a possible cause. Factor V Leiden (FVL) and prothrombin gene (G20210A) mutations are the most common types of hereditary thrombophilias, but are usually undiagnosed because most carriers are asymptomatic. The relationship between FVL, G20210A, and RPL has been investigated with conflicting results. This study analyzed existing data to determine whether an association exists. Methods: A systematic review of the literature was performed. Only case-control studies that defined RPL as 2 or more pregnancy losses in the first or second trimester and that confirmed mutations by DNA analysis were included. Sixteen studies were selected for the FVL meta-analysis and 7 for the G20210A analysis. Stratified and multivariate logistic regression analyses were performed with the use of aggregate data. Results were confirmed by means of fixed- and random-effects meta-analyses models. Results: The combined odds ratios for the association between RPL and FVL and between RPL and G20210A were 2.0 (95% confidence interval, 1.5-2.7; P<.001) and 2.0 (95% confidence interval, 1.0-4.0; P = .03), respectively. Similar results were produced by the logistic regression and both fixed- and random-effects meta-analysis models. Conclusions: Carriers of FVL or prothrombin gene mutations have double the risk of experiencing 2 or more miscarriages compared with women without thrombophilias. Hereditary thrombophilias may be an unrecognized cause of RPL. We recommend testing for these mutations in women with RPL. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
20. ACTIVE TREATMENT OR NO TREATMENT (ACTORNOT) FOR PERSISTING PREGNANCY OF UNKNOWN LOCATION; A RANDOMIZED CLINICAL TRIAL.
- Author
-
Barnhart, Kurt T., Hansen, Karl R., Stephenson, Mary D., Steiner, Anne Z., Jungheim, Emily S., Hoeger, Kathleen, Krawetz, Stephen A., Senapati, Suneeta, Cedars, Marcelle I., Huang, Hao, Eisenberg, Esther, Santoro, Nanette, and Zhang, Heping
- Subjects
- *
CLINICAL trials , *ECTOPIC pregnancy , *HIGH-risk pregnancy , *PREGNANCY - Published
- 2020
- Full Text
- View/download PDF
21. Scurvy and embryo culture.
- Author
-
Barnhart, Kurt T.
- Subjects
- *
HUMAN in vitro fertilization , *EMBRYO transfer , *FEMALE infertility , *PREGNANCY , *CHILDBIRTH , *SCURVY - Published
- 2018
- Full Text
- View/download PDF
22. In vitro fertilization add-ons for the endometrium: it doesn't add-up.
- Author
-
Lensen, Sarah, Shreeve, Norman, Barnhart, Kurt T, Gibreel, Ahmed, Ng, Ernest Hung Yu, and Moffett, Ashley
- Subjects
- *
INFERTILITY treatment , *BIRTH rate , *ENDOMETRIUM , *FERTILITY , *FERTILIZATION in vitro , *INFERTILITY , *EVALUATION of medical care , *PREGNANCY , *EVIDENCE-based medicine , *FETAL development , *TREATMENT effectiveness , *FERTILITY drugs - Abstract
The probability of live birth from an in vitro fertilization (IVF) cycle is modest. Many additional treatments (add-ons) are available which promise to improve the success of IVF. This review summarizes the current evidence for common IVF add-ons which are suggested to improve endometrial receptivity. Systematic reviews of randomized controlled trials and individual trials were included. Five add-ons were included: immune therapies, endometrial scratching, endometrial receptivity array, uterine artery vasodilation, and human chorionic gonadotropin instillation. The results suggest there is no robust evidence that these add-ons are effective or safe. Many IVF add-ons are costly, consuming precious resources which may be better spent on evidence-based treatments or further IVF. Large randomized controlled trials and appropriate safety assessment should be mandatory before the introduction of IVF add-ons into routine practice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. BhCG doubling time in early gestation in symptomatic patients with an intrauterine pregnancy: the curves redefined.
- Author
-
Barnhart, Kurt T., Rinaudo, Paolo F., Sammel, Mary D., Zhou, Lan, Guo, Wenshang, and Hummel, Amy
- Subjects
- *
CHORIONIC gonadotropins , *PREGNANCY , *EMERGENCY medical services , *MENSTRUAL cycle , *MISCARRIAGE - Published
- 2003
- Full Text
- View/download PDF
24. Pregnancy registry: three-year follow-up of children conceived from letrozole, clomiphene, or gonadotropins.
- Author
-
Legro, Richard S., Diamond, Michael P., Coutifaris, Christos, Schlaff, William D., Alvero, Ruben, Casson, Peter, Christman, Gregory M., Rosen, R. Mitchell, Cedars, Marcelle I., Hansen, Karl R., Robinson, Randal, Baker, Valerie, Usadi, Rebecca, Dodson, William C., Estes, Stephanie J., Kunselman, Allen, Stetter, Christina, Barnhart, Kurt T., Coward, R. Matthew, and Trussell, J.C.
- Subjects
- *
ACADEMIC medical centers , *MULTIPLE pregnancy , *POLYCYSTIC ovary syndrome , *PREGNANCY , *CHILD development , *MINORS , *CLOMIPHENE , *RESEARCH , *CLINICAL trials , *AGE distribution , *RESEARCH methodology , *CHILD behavior , *COGNITION , *ACQUISITION of data , *EVALUATION research , *MEDICAL cooperation , *INFERTILITY , *GONADOTROPIN , *FERTILITY drugs , *PREGNANCY outcomes , *TREATMENT effectiveness , *WEIGHT gain , *COMPARATIVE studies , *FERTILITY , *QUESTIONNAIRES , *RESEARCH funding , *INDUCED ovulation , *BODY language , *LONGITUDINAL method - Abstract
Objective: To study the development of children conceived from non-IVF infertility treatments consisting of gonadotropins, clomiphene, or letrozole.Design: Prospective cohort study.Setting: U.S. academic health centers.Patient(s): Children of women with polycystic ovary syndrome who conceived with letrozole (LTZ) or clomiphene (CC) in the PPCOS II study or women with unexplained infertility (AMIGOS study) who conceived with LTZ, CC, or gonadotropin (GN).Intervention(s): Longitudinal annual follow-up from birth to age 3.Main Outcome Measure(s): Scores from Ages and Stages Developmental Questionnaire (ASQ), MacArthur-Bates Communicative Development Inventory (MCDI), and annual growth.Result(s): One hundred eighty-five children from 160 families participated in at least one follow-up evaluation from the two infertility trials. Most multiple gestations in the follow-up study resulted from GN treatment (n = 14) followed by CC (n = 6) and LTZ (n = 3). There were no significant differences among the three groups at any time point with respect to abnormal scores on the ASQ. On the MCDI Words and Gestures, the LTZ group scored significantly higher than the GN group for most items (phrases, early gestures, later gestures, and total gestures). Children in the CC group scored significantly higher than the GN group for the later gestures and total gestures items.Conclusion(s): Differences in growth and cognitive developmental rates among children conceived with first-line infertility therapies, including LTZ, are relatively minor and likely due to differences in multiple pregnancy rates. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
25. Impact of method of endometrial preparation for frozen blastocyst transfer on pregnancy outcome: a retrospective cohort study.
- Author
-
Alur-Gupta, Snigdha, Hopeman, Margaret, Berger, Dara S., Gracia, Clarisa, Barnhart, Kurt T., Coutifaris, Christos, and Senapati, Suneeta
- Subjects
- *
EMBRYO transfer , *BLASTOCYST , *FROZEN human embryos , *PREGNANCY , *BIRTH rate , *HUMAN in vitro fertilization , *CRYOPRESERVATION of organs, tissues, etc. , *ENDOMETRIUM , *ESTROGEN , *LONGITUDINAL method , *LUTEAL phase , *RESEARCH funding , *RETROSPECTIVE studies , *IMPACT of Event Scale - Abstract
Objective: To determine whether live birth rates differ by type of endometrial preparation in frozen embryo transfer (FET) cycles.Design: Retrospective cohort study.Setting: Academic fertility center.Patient(s): Reproductive-aged women undergoing autologous vitrified-warmed blastocyst FETs.Intervention(s): Comparison of two methods of endometrial preparation: programmed FET (known as group A: luteal phase GnRH agonist suppression, oral E2, and IM P starting 5 days before ET) versus unstimulated FET (known as group B: hormone and ultrasound monitoring for follicle collapse to time transfer).Main Outcome Measure(s): Live birth rates in group A and group B.Result(s): Group A consisted of 923 cycles, and group B consisted of 105. When stratified by age at transfer, there was no difference in any of the measured outcomes, including live birth rates in adjusted models (adjusted odds ratio 1.0, 95% confidence interval 0.6-1.5), except in patients older than 40 years. These patients in group B had a 100% failure rate (n = 6).Conclusion(s): In most women, unstimulated endometrial preparation with luteal support before FET has similar success compared with exogenous hormone preparation. Women older than 40 years may benefit from programmed FETs owing to the challenges of increased cycle variability expected in that age group. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
26. APPLICATION OF A MULTIPLEX PLATFORM TO IDENTIFY NOVEL BIOMARKERS FOR PREGNANCY LOCATION AND VIABILITY.
- Author
-
Lee, Iris TIENLYNN., Koelper, Nathan C., Schreiber, Courtney A., Senapati, Suneeta, Sammel, Mary, and Barnhart, Kurt T.
- Subjects
- *
BIOMARKERS , *PREGNANCY - Published
- 2022
- Full Text
- View/download PDF
27. Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes.
- Author
-
Steiner, Anne Z., Diamond, Michael P., Legro, Richard S., Schlaff, William D., Barnhart, Kurt T., Casson, Peter R., Christman, Gregory M., Alvero, Ruben, Hansen, Karl R., Geisler, William M., Thomas, Tracey, Santoro, Nanette, Zhang, Heping, Eisenberg, Esther, and Reproductive Medicine Network
- Subjects
- *
CHLAMYDIA trachomatis , *IMMUNOGLOBULINS , *REPRODUCTIVE health , *HEALTH outcome assessment , *HUMAN fertility , *FALLOPIAN tubes , *CHLAMYDIA infection diagnosis , *ULTRASONIC imaging of fallopian tubes , *INFERTILITY treatment , *CHI-squared test , *BIRTH rate , *CHLAMYDIA infections , *COMPARATIVE studies , *ECTOPIC pregnancy , *ENZYME-linked immunosorbent assay , *HUMAN reproductive technology , *INFERTILITY , *RESEARCH methodology , *EVALUATION of medical care , *MEDICAL cooperation , *MULTIVARIATE analysis , *PREGNANCY , *REGRESSION analysis , *RESEARCH , *RESEARCH funding , *RISK assessment , *SERODIAGNOSIS , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *PREDICTIVE tests , *BACTERIAL antibodies , *ODDS ratio , *DISEASE complications , *DIAGNOSIS - Abstract
Objective: To determine if Chlamydia trachomatis (C. trachomatis) seropositivity, as detected by the C. trachomatis elementary body (EB)-based enzyme-linked immunosorbent assay [EB ELISA] predicts pregnancy and pregnancy outcome among infertile women with documented tubal patency.Design: Cohort study.Setting: Outpatient clinics.Patient(s): In all, 1,250 infertile women with documented tubal patency enrolled in 1 of 2 randomized controlled trials: Pregnancy in Polycystic Ovary Syndrome II; and the Assessment of Multiple Intrauterine Gestations From Ovarian Stimulation.Intervention(s): Sera were analyzed for anti-C. trachomatis immunoglobulin G (IgG)1 and IgG3 antibodies, using a research C. trachomatis EB ELISA. The optical density (OD)405 readings of ≥ 0.35 and ≥ 0.1 were considered positive for IgG1 and IgG3, respectively.Main Outcome Measure(s): Primary outcomes included pregnancy, live birth, and ectopic pregnancy. Log-linear regression was used to determine the relative risk after adjusting for age, race, treatment medication, smoking status, and current alcohol use.Result(s): A total of 243 (19%) women were seropositive for anti-C. trachomatis IgG3. They tended to be nonwhite and smokers. Anti-C. trachomatis IgG3 seropositive women were significantly less likely to conceive (risk ratio [RR] 0.65, 95% confidence interval [CI] 0.52-0.83) or to have a live birth (RR 0.59, 95% CI 0.43-0.80); these associations were weakened after adjusting for number of hysterosalpingography-documented patent tubes (RR 0.73, 95% CI 0.56-0.97) and (RR 0.73, 95% CI 0.50-1.04), respectively. Anti-C. trachomatis IgG3 seropositive women who conceived had a ×2.7 risk (95% CI 1.40-5.34) of ectopic pregnancy.Conclusion(s): Even in the presence of tubal patency, anti-C. trachomatis IgG3 seropositivity is associated with a lower likelihood of pregnancy. Anti-C. trachomatis IgG3 seropositive women have as high as 3 times the risk of ectopic pregnancy.Clinical Trial Registration Number: PPCOSII: NCT00719186 and AMIGOS: NCT01044862. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
28. Increasing burden of institutional review in multicenter clinical trials of infertility: the Reproductive Medicine Network experience with the Pregnancy in Polycystic Ovary Syndrome (PPCOS) I and II studies
- Author
-
Schlaff, William D., Zhang, Heping, Diamond, Michael P., Coutifaris, Christos, Casson, Peter R., Brzyski, Robert G., Christman, Gregory M., Barnhart, Kurt T., Trussell, J.C., Krawetz, Stephen A., Snyder, Peter J., Ohl, Dana, Santoro, Nanette, Eisenberg, Esther, Huang, Hao, Legro, Richard S., and Reproductive Medicine Network
- Subjects
- *
INFERTILITY , *REPRODUCTIVE health , *PREGNANCY , *POLYCYSTIC ovary syndrome , *INSTITUTIONAL review boards , *MEDICAL experimentation on humans , *ETHICS , *CLINICAL trials , *INFERTILITY treatment , *POLYCYSTIC ovary syndrome treatment , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *EVALUATION research , *DISEASE complications , *DIAGNOSIS - Abstract
Unlabelled: Many clinical investigators think that the burden of Institutional Review Board (IRB) requirements has been consistently increasing over recent years, although there are few objective data describing these trends. Over a period of 7 years, the Reproductive Medicine Network observed a significant increase in the size and requirements of IRB submissions and significant variability of IRB performance in reviewing multicenter trials. These additional regulatory and administrative demands represent substantial burdens to researchers and to the IRBs themselves. It is timely to consider whether these changes better protect the interests and safety of human research participants.Clinical Trial Registration: ClinicalTrials.gov NCT00068861 and NCT00719186. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
29. Perinatal morbidity after in vitro fertilization is lower with frozen embryo transfer
- Author
-
Kansal Kalra, Suleena, Ratcliffe, Sarah J., Milman, Lauren, Gracia, Clarisa R., Coutifaris, Christos, and Barnhart, Kurt T.
- Subjects
- *
HUMAN in vitro fertilization , *TREATMENT effectiveness , *HUMAN embryo transfer , *OVARIES , *NEONATAL diseases , *PREGNANCY , *LOGISTIC regression analysis , *FETAL growth retardation , *MISCARRIAGE , *CONCEPTION - Abstract
Objective: To study the association of perinatal outcome and IVF transfer type in a group of infertility patients with standardized treatment and similar prognosis.Design: Retrospective cohort study.Setting: University-based infertility center, January 1998 to June 2006.Patient(s): Two hundred eighteen IVF pregnancies after fresh embryo transfer (ET); 122 IVF pregnancies after frozen ET.Intervention(s): Assessment of perinatal outcome in fresh versus frozen ET pregnancies.Main Outcome Measure(s): Pregnancy outcomes after fresh versus frozen embryo transfer (ET). Primary outcome was a composite of three events: preterm delivery, intrauterine growth restriction, or low birth weight. Secondary outcomes were subtypes of pregnancy loss. Associations were assessed using multivariate logistic regression.Result(s): The final sample included 340 pregnancies: 218 fresh and 122 frozen ETs. Singleton pregnancy was less likely after transfer of fresh embryos (odds ratio [OR] 0.39, 95% confidence interval [CI] 0.23-0.67), and pregnancies after fresh ET were more likely to end in first-trimester loss (OR 1.82, 95% CI 1.05-3.13). Composite adverse outcome after transfer of fresh (44.0%) versus frozen (32.6%) embryos was higher (OR 1.52, 95% CI 0.90-2.56) and was strongly associated with twin gestation (OR 23.82, 95% CI 11.16-50.82).Conclusion(s): Perinatal morbidity is higher in IVF pregnancies conceived after a fresh ET compared with a frozen ET. Although some differences are related to conception with twin gestations, these findings suggest that adverse outcomes may be related to differences in IVF procedures. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
30. WHEN ABNORMAL HCG LEVELS RESULT IN A NORMAL PREGNANCY.
- Author
-
Bollig, Kassie Jean, Finlinson, Alex R., Coutifaris, Christos, Schust, Danny J., and Barnhart, Kurt T.
- Subjects
- *
PREGNANCY - Published
- 2021
- Full Text
- View/download PDF
31. OBSTETRICAL OUTCOMES OF LATE PRESENTING INTRAUTERINE PREGNANCIES.
- Author
-
Dawodu, Olanrewaju, Wu, Jessica K., Gallop, Robert, and Barnhart, Kurt T.
- Subjects
- *
PREGNANCY - Published
- 2021
- Full Text
- View/download PDF
32. Factors influencing adverse perinatal outcomes in pregnancies achieved through use of in vitro fertilization
- Author
-
Chung, Karine, Coutifaris, Christos, Chalian, Raffi, Lin, Kathleen, Ratcliffe, Sarah J., Castelbaum, Arthur J., Freedman, Martin F., and Barnhart, Kurt T.
- Subjects
- *
FERTILIZATION in vitro , *HUMAN fertility , *PREGNANCY , *EMBRYO transfer - Abstract
Objective: To determine the associations of specific components of IVF treatment with abnormal perinatal outcomes. Design: Case-control study. Setting: University-based and community-based infertility centers. Patient(s): All viable pregnancies achieved through IVF procedures performed between January 1999 and March 2004. Intervention(s): None. Main Outcome Measure(s): Infertility etiology, gonadotropin exposure, embryo manipulation, and quality. Result(s): Of 455 viable pregnancies identified during the study period, 435 met inclusion criteria. While adjusting for maternal age, race, parity, body mass index, infertility center, and year of IVF procedure, multiple gestations were associated with a 12-fold increased risk of poor perinatal outcome compared to singletons. Ovarian hyperstimulation syndrome significantly increased the risk more than 3-fold (odds ratio = 3.14; 95% confidence interval, 1.08–9.14), while endometrial thickness was found to have a significant protective effect (odds ratio = 0.89; 95% confidence interval, 0.80–0.99). We found no effect of etiology of infertility, dose or type of medication used for stimulation, use of embryo-manipulation techniques, or quality on perinatal outcome. Conclusion(s): These data confirm and quantify the risk of perinatal morbidity associated with multiple births. After adjusting for multiple births, ovarian hyperstimulation syndrome and suboptimal endometrial development are associated with adverse outcomes in pregnancies achieved through IVF. Our findings suggest that it may be the endometrium rather than the embryo that influences fetal growth and perinatal outcomes after IVF. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
33. Application of redefined human chorionic gonadotropin curves for the diagnosis of women at risk for ectopic pregnancy
- Author
-
Seeber, Beata E., Sammel, Mary D., Guo, Wensheng, Zhou, Lan, Hummel, Amy, and Barnhart, Kurt T.
- Subjects
- *
PREGNANCY , *OBSTETRICS , *GONADOTROPIN , *ECTOPIC pregnancy - Abstract
Objective: To validate recently characterized curves of hCG rise and fall that are seen in viable and nonviable pregnancies in a population of women who have pregnancies of unknown location. Design: Historical cohort study. Setting: University hospital. Patient(s): One thousand two hundred forty-nine women with symptomatic early pregnancies. Intervention(s): None. Main Outcome Measure(s): Comparison of observed hCG values to predicted hCG values; time to diagnosis of ectopic pregnancy; accuracy of diagnosis. Result(s): Of the 1,249 patients included in this study, 196 had ectopic pregnancy (EP); 261, intrauterine pregnancy (IUP); and 792, spontaneous abortion (SAB). By determining the rate of change in hCG values from two consecutive visits and comparing them with a minimal rise of 35% in 2 days (the bound that is defined by the 99.9% confidence interval [CI] for the rise of hCG in an IUP) or a minimal fall of 21%–35% (the bound that is defined by the 90% CI for the fall of hCG in an SAB), we were able to make the diagnosis of EP an average of 2.5 days sooner than by standard clinical practice. Only 12% of patients had an EP go undiagnosed by using these rules, because the curve of rise or fall of their hCG mimicked that of a non-EP gestation. Conclusion(s): Recently redefined curves of rise and fall in hCG for IUP and SAB are valid for clinical use on the basis of our application to this large cohort of patients. Using them can shorten the time needed to make the diagnosis of EP. Use of a more conservative cutoff for minimal rise in hCG, one as slow as 35% over 2 days, to characterize a potentially viable gestation would minimize potential interruption of a desired pregnancy. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
34. Acceptability of five nonoxynol-9 spermicides
- Author
-
Raymond, Elizabeth G., Chen, Pai Lien, Condon, Sean, Luoto, Joanne, Barnhart, Kurt T., Creinin, Mitchell D., Poindexter, Alfred, Wan, Livia, Martens, Mark, Schenken, Robert, and Blackwell, Richard
- Subjects
- *
CONTRACEPTIVE drugs , *VAGINAL contraceptives , *SPERMATOZOA , *PREGNANCY - Abstract
Objective: To examine the acceptability of five nonoxynol-9 (N-9) spermicides.Methods: We analyzed data from a randomized trial of five products, including three gels containing different amounts of N-9 per dose, a film and a suppository. In the trial, 1536 participants were asked to use the assigned spermicide for 7 months and to complete questionnaires 4 weeks after admission and at discontinuation.Results: Overall, 43% of participants liked their spermicide "very much." This proportion was higher in the three gel groups than in the suppository and film groups. Difficulty with insertion, messiness and discontent with timing of insertion were common complaints in all groups. After adjustment for selected baseline factors, acceptability on the first questionnaire was not related to duration or consistency of subsequent spermicide use or to subsequent time to pregnancy.Conclusions: In this study, all five spermicides were considered acceptable by most users. Acceptability did not appear to influence spermicide use or pregnancy risk. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
35. Predicting first trimester pregnancy outcome: derivation of a multiple marker test.
- Author
-
Senapati, Suneeta, Sammel, Mary D., Butts, Samantha F., Takacs, Peter, Chung, Karine, and Barnhart, Kurt T.
- Subjects
- *
FIRST trimester of pregnancy , *BIOMARKERS , *PROGESTERONE , *GESTATIONAL age , *COHORT analysis , *ENZYME-linked immunosorbent assay , *COMPARATIVE studies , *ECTOPIC pregnancy , *IMMUNOASSAY , *RESEARCH methodology , *EVALUATION of medical care , *MEDICAL cooperation , *MISCARRIAGE , *PEPTIDE hormones , *PHARMACOKINETICS , *PREGNANCY , *PREGNANCY proteins , *RESEARCH , *RESEARCH funding , *EVALUATION research , *PREDICTIVE tests , *CASE-control method , *RECEIVER operating characteristic curves , *DIAGNOSIS ,RESEARCH evaluation - Abstract
Objective: To predict first trimester pregnancy outcome using biomarkers in a multicenter cohort.Design: Case-control study.Setting: Three academic centers.Patient(s): Women with pain and bleeding in early pregnancy.Intervention(s): Sera from women who were 5-12 weeks' gestational age with ectopic pregnancy (EP), viable intrauterine pregnancy (IUP), and miscarriage/spontaneous abortion (SAB) was analyzed by ELISA and immunoassay for activin A, inhibin A, P, A Disintegrin And Metalloprotease-12, pregnancy-associated plasma protein A (PAPP-A), pregnancy specific B1-glycoprotein (SP1), placental-like growth factor, vascular endothelial growth factor, glycodelin (Glyc), and hCG. Classification trees were developed to optimize sensitivity/specificity for pregnancy location and viability.Main Outcome Measure(s): Area under receiver operating characteristic curve, sensitivity, specificity, and accuracy of first trimester pregnancy outcome.Result(s): In 230 pregnancies, the combination of trees to maximize sensitivity and specificity resulted in 73% specificity (95% confidence interval (CI) 0.65-0.80) and 31% sensitivity (95% CI 0.21-0.43) for viability. Similar methods had 21% sensitivity (95% CI 0.12-0.32) and 33% specificity (95% CI 0.26-0.41) for location. Activin A, Glyc, and A Disintegrin And Metalloprotease-12 definitively classified pregnancy location in 29% of the sample with 100% accuracy for EP. Progesterone and PAPP-A classified the viability in 61% of the sample with 94% accuracy.Conclusion(s): Multiple marker panels can distinguish pregnancy location and viability in a subset of women at risk for early pregnancy complications. This strategy of combining markers to maximize sensitivity and specificity results in high accuracy in a subset of subjects. Activin A, ADAM12, and Glyc are the most promising markers for pregnancy location; P and PAPP-A for viability. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
36. Impact of endometriosis on in vitro fertilization outcomes: an evaluation of the Society for Assisted Reproductive Technologies Database.
- Author
-
Senapati, Suneeta, Sammel, Mary D., Morse, Christopher, and Barnhart, Kurt T.
- Subjects
- *
ENDOMETRIOSIS , *FERTILIZATION in vitro , *HEALTH outcome assessment , *REPRODUCTIVE technology , *MEDICAL databases , *DIAGNOSIS of endometriosis , *INFERTILITY treatment , *BIRTH rate , *CRYOPRESERVATION of organs, tissues, etc. , *DATABASES , *EMBRYO transfer , *FERTILITY , *EVALUATION of medical care , *INFERTILITY , *PREGNANCY , *TIME , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DISEASE complications , *DIAGNOSIS - Abstract
Objective: To assess the impact of endometriosis, alone or in combination with other infertility diagnoses, on IVF outcomes.Design: Population-based retrospective cohort study of cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database.Setting: Not applicable.Patient(s): A total of 347,185 autologous fresh and frozen assisted reproductive technology cycles from the period 2008-2010.Intervention(s): None.Main Outcome Measure(s): Oocyte yield, implantation rate, live birth rate.Result(s): Although cycles of patients with endometriosis constituted 11% of the study sample, the majority (64%) reported a concomitant diagnosis, with male factor (42%), tubal factor (29%), and diminished ovarian reserve (22%) being the most common. Endometriosis, when isolated or with concomitant diagnoses, was associated with lower oocyte yield compared with those with unexplained infertility, tubal factor, and all other infertility diagnoses combined. Women with isolated endometriosis had similar or higher live birth rates compared with those in other diagnostic groups. However, women with endometriosis with concomitant diagnoses had lower implantation rates and live birth rates compared with unexplained infertility, tubal factor, and all other diagnostic groups.Conclusion(s): Endometriosis is associated with lower oocyte yield, lower implantation rates, and lower pregnancy rates after IVF. However, the association of endometriosis and IVF outcomes is confounded by other infertility diagnoses. Endometriosis, when associated with other alterations in the reproductive tract, has the lowest chance of live birth. In contrast, for the minority of women who have endometriosis in isolation, the live birth rate is similar or slightly higher compared with other infertility diagnoses. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.